Trump’s tariff threat on generic drugs: Why this matters for Indian pharma companies
US President Donald Trump announced plans to raise tariffs on generic drugs by 100% after two years and 200% thereafter, aiming to encourage domestic pharmaceutical production. This move follows previous threats and is part of a broader strategy to attract investment in the US, although actual tariffs have often been exempted. Indian pharmaceutical companies are already adjusting their investment strategies in response to these developments, which could significantly impact their operations in the US market.